Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for $10 billion

Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for  billion


Test tubes are seen in front of a displayed Abbvie logo in this illustration taken, May 21, 2021.

Dado Ruvic | Reuters

Biotech stocks rose Thursday as AbbVie announced plans to buy cancer drug developer ImmunoGen for $10.1 billion. 

Shares of ImmunoGen jumped more than 80% on Thursday, putting it on track for its highest close since November 2000. Meanwhile, AbbVie’s stock rose more than 2%. 

ImmunoGen develops cancer drugs called antibody-drug conjugates, or ADCs, which are designed to directly kill cancer cells and spare healthy ones. Shares of other biotech companies developing ADCs, which are among the hottest areas in the pharmaceutical industry, jumped on the news of the buyout. 

That includes Sutro BioPharma‘s stock, which spiked about 16% on Thursday and shares of Mersana Therapeutics, which rose nearly 17%. Shares of ADC Therapeutics also popped about 15% on Thursday.

The SPDR S&P Biotech ETF, which focuses on small and midsize biotech companies, rose 3% on Thursday. The Nasdaq Biotechnology Index advanced more than 1%.

Under the terms of the deal, AbbVie will pay $31.26 a share in cash for ImmunoGen, a roughly 95% premium to Wednesday’s closing price. AbbVie said it expects to complete the acquisition, which aims to strengthen its oncology pipeline, in the middle of 2024.

Guggenheim analyst Michael Schmidt said the price of the deal reflects the “increasing interest we have seen from large biopharma companies wanting to increase their exposure” in ADCs, which he called an “attractive area.”

For example, Pfizer agreed to acquire Seagen, a pioneer in ADCs, for $43 billion earlier this year. Merck and Daiichi Sankyo also recently agreed to jointly develop and commercialize three potential ADCs in a deal worth up to $22 billion.



Source

Healthy Returns: What to know about a CDC vaccine panel’s votes against a mercury preservative in flu shots
Health

Healthy Returns: What to know about a CDC vaccine panel’s votes against a mercury preservative in flu shots

Biostatistician and epidemiologist Martin Kulldorff, MD, PhD, and Dr. Mina Zadeh, ACIP Executive Secretary, CDC, look on as people present their information to members of the Advisory Committee on Immunization Practices, as the U.S. Centers for Disease Control and Prevention’s (CDC) advisory panel for vaccines convenes, in Atlanta, Georgia, U.S. June 25, 2025. Megan Varner […]

Read More
Medicaid cuts in Trump’s ‘big beautiful’ bill will leave millions uninsured, threaten rural hospitals
Health

Medicaid cuts in Trump’s ‘big beautiful’ bill will leave millions uninsured, threaten rural hospitals

An aerial view of Valley Health Hampshire Memorial Hospital on June 17, 2025 in Romney, W.V. Ricky Carioti | The Washington Post | Getty Images President Donald Trump’s “big, beautiful bill” would make sweeping changes to U.S. health care, leaving millions of vulnerable Americans without health insurance and threatening the hospitals and centers that provide […]

Read More
Moderna’s flu vaccine shows positive late-stage trial results, paving way for combination Covid shot
Health

Moderna’s flu vaccine shows positive late-stage trial results, paving way for combination Covid shot

The Moderna Inc. headquarters in Cambridge, Massachusetts, on March 26, 2024. Adam Glanzman | Bloomberg | Getty Images Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and the company’s separate combination flu and […]

Read More